Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abbisko Cayman Limited ( (HK:2256) ) has provided an update.
Abbisko Therapeutics has dosed the first U.S. patient in the expansion phase of a global Phase I trial of irpagratinib, its highly selective oral FGFR4 inhibitor for patients with FGF19-overexpressing advanced hepatocellular carcinoma. The drug has received both Fast Track designation from the U.S. FDA and Breakthrough Therapy designation in China, reflecting regulators’ recognition of its potential to address a high unmet need.
Early data from the China cohort show durable antitumor activity and a favorable safety profile, with particularly strong responses in patients previously treated with immune checkpoint and multi-targeted kinase inhibitors. Combination Phase II data with atezolizumab also indicate robust efficacy and manageable safety, positioning irpagratinib as a promising candidate in first-line HCC treatment and underscoring Abbisko’s push to accelerate global development and commercialization.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a clinical-stage biopharmaceutical group focused on developing small-molecule targeted therapies, primarily through its subsidiary Abbisko Therapeutics. The company is concentrating on precision oncology, with a particular emphasis on advanced hepatocellular carcinoma and other solid tumors driven by specific molecular alterations.
Average Trading Volume: 1,832,094
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.6B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.